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ABSTRACT  
Objective: Synthesis and antimicrobial evaluation of regioisomers of allyl phenyl ethers derived 1, 2, 4-triazoles. 
Methods: A series of new 1,2,4-triazole derivatives of allyl phenyl ethers were synthesized by reacting a mixture of regio isomers 1-(3-bromo-2-
methoxypropoxy)-arene and 1-(2-bromo-3-methoxypropoxy)-arene with 1,2,4-triazole in presence of K2CO3 and DMF at 80oC in good yields. Allyl 
phenyl ethers 1(a-f) were synthesized by refluxing the substituted phenols with allyl bromide in the presence of K2CO3 and acetone in excellent 
yields. The newly synthesized compounds were characterized by IR, 1HNMR, Mass spectral studies and elemental analysis. These compounds were 
also screened for their In-vitro antibacterial and antifungal activities. 
Results: Allyl phenyl ethers derived 1,2,4-triazol derivatives were synthesized in good yields. 
Conclusion: Preliminary results revealed that some of the synthesized compounds were showed promising antibacterial and antifungal activity. 
Keywords: 1, 2, 4-triazole, Antibacterial activity and Antifungal activity. 
 
INTRODUCTION 
Nowadays research is concentrated towards the introduction of new 
and safe therapeutic agents of clinical importance. The heterocyclic 
compounds are enjoying their importance as being the center of 
activity. The nitrogen containing heterocyclic compounds were 
found in abundance in most of the medicinal compounds. The 
presence of three nitrogen hetero-atoms in five membered ring 
systems defines an interesting class of compounds, the triazoles. 
1,2,4-Triazole derivatives are known to exhibit a wide range of 
biological activities, such as antibacterial [1–4], antifungal [4–5], 
analgesic [6], anticancer [7-8], antiviral [9], antitubercular [10-11], 
anti-inflammatory [12], anticonvulsant [13-14], antidepressant [15] 
and central nervous system (CNS) [16]. Therefore, the synthesis of 
some new 1,2,4-triazole derivatives attracts much interest in 
heterocyclic chemistry. Keeping in view of the above facts and our 
search on biologically potent molecules, we herein report the 
synthesis of some new allyl phenyl ethers derived 1,2,4-triazoles 
and their microbial activity. 
MATERIALS AND METHODS 
The chemicals/reagents used were purchased from sigma-aldrich 
chemicals (India) and Merck Chemicals (India). Reactions were 
monitored by pre-coated TLC (silica gel GF 254 [E.Merck]) plates. 
The IR spectra were recorded by using Perkin Elmer FTIR 
spectrometer using a thin film on KBr pellets and frequencies were 
expressed in cm-1. The 1HNMR spectra were recorded on Brucker 
300 and 400MHz spectrometer using TMS as internal standard. The 
Chemical shifts values were reported in ppm and given in δ units. 
The Mass spectra were recorded by the EI process. The elemental 
analysis were performed on Perkin Elmer CHNS/O analyzer 2400. 
The synthetic route for 1, 2, 4-triazole derivatives of allyl aryl ethers 
was depicted in scheme 1.The substituted Phenols were used as 
starting materials. The reaction of substituted phenols with allyl 
bromide in the presence of K2CO3 and acetone yielded O-allyl ethers 
1(a-f) in excellent yields [17-20]. The reaction of allyl aryl ethers 
1(a-f) with N-Bromosuccinimide and a catalytic amount of H2SO4 in 
methanol at reflux temperature yielded a mixture of regioisomers 
(Markovnikov’s –anti Markovnikov’s products) [21-22]. Though 
Markovnikov’s rule predicts the major formation of isomer-A, the 
formation of isomer-B must be allowed due to the steric hindrance 
of Phenolic group. The separation of regioisomers was not achieved 
at this stage. The mixture of regioisomers were carried to further 
reaction with 1,2,4-triazole in presence of K2CO3 and DMF to afford 
1-[3-(Aryloxy)-2-methoxypropyl]-1H-1,2,4-triazole and 1-(1-
(Aryloxy)-3-methoxypropan-2-yl)-1H-1,2,4-triazole [23-25]. The 
positional isomers of 1,2,4-triazole derivatives were separated by 
NP-HPLC method using a gradient mixture of n-hexane and 
isopropanol as eluent.  
General procedure for O-allylation 
To a suspension of substituted phenols (1.0 equiv) and K2CO3 (2.5 
equiv) in acetone (10 mL) was added allylbromide (1.05 equiv) and 
refluxed for 12h. After completion of the reaction, the suspension 
was filtered. The solvent was evaporated to dryness, quenched with 
water (10 mL) and extracted with ethyl acetate (3X10 mL). The 
combined organic layer thus obtained was washed with brine, dried 
over anhydrous Na2SO4 and evaporated in reduced pressure to 
afford the crude. The crude was purified by column chromatography 
on silica gel (60-120 mesh) using (10-15%) ethyl acetate-hexane 
mixture as eluent to afford the pure products 1(a-f). The spectral 
data of O-allyl ethers 1(a-f) were matched with literature values 
[18].  
General procedure for synthesis of 1-(3-bromo-2-methoxy 
propoxy)-arene and 1-(2-bromo-3-methoxypropoxy)-arene 2(a-f) 
To a stirred solution of 1(a-f) (5.93 mmol) in methanol (10 mL) was 
added N-Bromosuccinamide (5.93 mmol) followed by catalytic 
amount of H2SO4 at 00C. Then reaction mass was refluxed for 2h. The 
reaction was monitored by TLC. Then, the solvent was evaporated 
under reduced pressure to afford crude oil. The crude was diluted 
with ice cold water (20 mL) and extracted with ethyl acetate (3X20 
mL). The combined extracts were washed with saturated NaHCO3 
solution, brine, dried over Na2SO4 and evaporated under reduced 
pressure to afford a mixture of positional isomers 2(a-f) as oils in 
good yields. Since these two regioisomers are not separable by 
Column Chromatography, the crude was used in the next step 
without further purification. 
General procedure for synthesis of 1-[3-(aryloxy)-2-methoxy 
propyl]-1H-1,2,4-triazole 3(a-f) and 1-[1-(aryloxy)-3-methoxy 
propan-2-yl]-1H-1,2,4-triazole 4(a-f) 
To a stirred solution of 2(a-f) (1.78 mmol) in DMF (5 mL), was 
added 1,2,4-triazole (1.78 mmol) and K2CO3 (3.57 mmol). The 
reaction was stirred at 80oC for 12 h. The reaction was monitored by 
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TLC. Then, the reaction mixture was diluted with ice cold water (10 
mL) and extracted with ethyl acetate (3X10 mL). The combined 
extracts were washed with brine, dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to afford a mixture of 
regioisomers (Isomer-C and Isomer-D). The regioisomers were 
separated by NP-Preparative HPLC method using a gradient mixture 
of (20-25%) 2-propanol in n-hexane as an eluent. 
 
 
i) K2CO3 / Acetone / Allylbromide / Reflux / 12h ii) NBS / H2SO4/ 
Methanol / Reflux / 2h iii) K2CO3 /DMF/ 80oC / 12h 
Scheme 1: Synthetic route for allyl phenyl ethers derived 1, 2, 4-
triazole derivatives 3(a-f) and 4(a-f). 
Spectral data  
2,4-dichlorophenyl prop-2-en-1-yl ether, 1a [18]: Yield:62%; 
Yellow oil: BP: 116-118/8 (OC/Torr): 1H NMR (CDCl3, 300MHz): δ 7.4 
(s, 1H), 7.20-7.18 (m, 1H), 6.9-6.8 (m, 1H), 6.2-6.1 (m, 1H), 5.5-5.4 
(m, 1H), δ 5.3-5.2 (m, 1H), 4.6-4.5 (m, 2H). EI-MS (m/z): 203 (M+H+) 
3,4-dichlorophenyl prop-2-en-1-yl ether, 1b [18]: Yield:75%; 
Yellow oil: BP: 123-124/10 (OC/Torr): 1H NMR (CDCl3, 300MHz): δ 
7.35-7.30 (m, 1H), 7.05 (s, 1H), 6.8-6.75 (m, 1H), 6.05-5.95 (m, 1H), 
5.42-5.38 (m, 1H), 5.31-5.29 (m, 1H), 4.51-4.50 (m, 2H); EI-MS 
(m/z): 203 (M+H+) 
2,6-dichlorophenyl prop-2-en-1-yl ether, 1c [18]: Yield: 78%; Oil: 
BP: 123-124/18 (OC/Torr): 1H NMR (CDCl3, 300MHz): δ 7.4-7.3 (m, 
2H), 7.1-6.98 (m, 1H), 6.2-6.1 (m, 1H), 5.5-5.4 (m, 1H), 5.3-5.25 (m, 
1H), 4.60-4.58 (m, 2H); EI-MS (m/z): 203 (M+H+) 
3-chlorophenyl prop-2-en-1-yl ether, 1d [18-19]: Yield: 66%; Oil: 
BP: 98-99/11 (OC/Torr): 1H NMR (CDCl3, 300MHz): δ 7.3-7.2 (m, 1H), 
7.0-6.98 (m, 1H), 6.9 (s, 1H), 6.81-6.79 (m, 1H), 6.2-6.1 (m, 1H), 5.5-
5.4 (m, 1H), 5.3-5.25 (m, 1H), 4.4-4.38 (d, 2H); EI-MS (m/z): 169 
(M+H+) 
4-chlorophenyl prop-2-en-1-yl ether, 1e [18]: Yield: 70%; Oil; BP: 
97-98/10 (OC/Torr): 1H NMR (CDCl3, 300MHz): δ 7.3-7.2 (m, 2H), 
6.9-6.8 (m, 2H), 6.1-5.98 (m, 1H), 5.42-5.25 (m, 2H), 4.57-4.50 (m, 
2H); EI-MS (m/z): 169 (M+H+) 
3,5-dimethylphenyl prop-2-en-1-yl ether, 1f [18]: Yield: 70%; Oil; 
BP: 98-99/9(OC/Torr): 1H NMR (CDCl3, 300MHz): δ 6.6 (s, 1H), 6.59 
(s, 2H), 6.18-6.0 (m, 1H), 5.41-5.38 (m, 1H), 5.3-5.2 (m, 1H), 4.57-
4.50 (m, 2H), 2.3 (s, 6H); EI-MS (m/z): 163 (M+H+) 
1-(3-bromo -2-methoxypropoxy)-2,4-dichlorobenzene and 1-
(2-bromo-3-methoxypropoxy)-2,4-dichlorobenzene, 2a: Oil; 
Yield 76%; 1H NMR (CDCl3, 300MHz): δ 7.39 (s, 1H), 7.20-7.19 (m, 
1H), 6.91-6.85 (m, 1H), 4.39-4.22 (m, 2H), 4.2-4.1(m, 1H), 3.9-3.8 (m, 
2H), 3.7-3.6 (m,1H), 3.55 (s, 1H), 3.43( s, 2H); EI-MS (m/z): 313 
(M+H+) 
4-(3-bromo-2-methoxypropoxy)-1,2-dichlorobenzene and 4-(2-
bromo-3-methoxypropoxy)-1,2-dichlorobenzene, 2b: Oil; Yield 
73%; 1H NMR (CDCl3, 300MHz): δ 7.36-7.30 (m, 1H), 7.1(s, 1H), 6.80-
6.76 (m, 1H), 4.3-4.2 (m, 2H), 4.1-4.05 (m, 1H), 3.8-3.7 (m, 2H), 3.60-
3.56 (m, 1H), 3.54 (s, 1H), 3.43 (s, 2H); EI-MS (m/z): 313 (M+H+) 
2-(3-bromo-2-methoxypropoxy)-1,3-dichlorobenzene and 2-(2-
bromo-3-methoxypropoxy)-1,3-dichlorobenzene, 2c: Oil; Yield 
78%;1H NMR (CDCl3, 300MHz): δ 7.30-7.31(m, 2H), 7.1-7.0 (m, 1H), 
4.4-4.2 (m, 2H), 4.1-4.05 (m, 1H), 3.82-3.57 (m, 6H), 3.56 (s, 1H), 
3.41(s, 2H); EI-MS (m/z): 313 (M+H+) 
  
Table 1: It Represents molecular formulas and yields of final compounds. 
S. No R/(Ar-OH) Formula of Isomer-C 3(a-f) Formula of Isomer-D 4(a-f)  Yield (%)              
1 2,4-Cl                3a/C12H13Cl2N3O2                       4a/C12H13Cl2N3O2                     75 
2 3,4-Cl                3b/C12H13Cl2N3O2                      4b/C12H13Cl2N3O2                           73 
3 2,6-Cl                3c/C12H13Cl2N3O 2                4c/C12H13Cl2N3O2                       80 
4 3-Cl                   3d/C12H14ClN3O2                 4d /C12H14ClN3O2                    78 
5 4-Cl                   3e/C12H14ClN3O2                 4e/C12H14ClN3O2                     85 
6 3,5-CH3              3f/C14H19N3O2                              4f/C14H19N3O2                                     82 
 
1-(3-bromo-2-methoxypropoxy)-3-chlorobenzene and 1-(2-
bromo-3-methoxypropoxy)-3-chlorobenzene, 2d: Oil; Yield 71%; 
1H NMR (CDCl3, 400MHz): δ 7.30-7.20 (m, 1H), 7.0-6.9 (m, 1H), 6.9 ( 
s,1H), 6.80-6.78 (m, 1H), 4.4-4.3 (m, 2H), 4.2-4.1 (m, 1H), 3.9-3.8 (m, 2H), 
3.7-3.6 (m, 1H), 3.58 (s, 1H), 3.41(s, 2H); EI-MS (m/z): 279 (M+H+) 
1-(3-bromo-2-methoxypropoxy)-4-chlorobenzene and 1-(2-
bromo-3-methoxypropoxy)-4-chlorobenzene, 2e: Oil; Yield 72%; 
1H NMR (CDCl3, 300MHz): δ 7.25 (m, 2H), 6.85 (m, 2H), 4.3-4.2 (m, 
2H), 4.1-4.05 (m, 1H), 3.8-3.6 (m, 3H), 3.56 (s, 1H), 3.41(s, 2H); EI-
MS (m/z): 279 (M+H+) 
1-(3-bromo-2-methoxypropoxy)-3,5-dimethylbenzene and 1-
(2-bromo-3-methoxypropoxy) -3,5-dimethylbenzene, 2f: Oil; 
Yield 75%; 1H NMR (CDCl3, 400MHz): δ 6.75 (s, 3H), 4.4-4.3 (m, 2H), 
4.2-4.1 (m, 1H), 3.9-3.8(m, 2H), 3.7-3.6 (m, 1H), 3.56 (s, 1H), 3.41(s, 
2H), 2.3 (s, 6H); EI-MS (m/z): 273 (M+H+) 
1-[3-(2,4-dichlorophenoxy)-2-methoxypropyl]-1H-1,2,4-
triazole, 3a: Semisolid; FT-IR(KBr, cm-1): 3053, 2931, 1503, 1482, 
1288, 1132, 1105,1012,746; 1HNMR (CDCl3, 300MHz): δ 8.4 (s, 1H), 
8.15 (s, 1H), 7.4 (s, 1H), 7.22-7.18 (m, 1H), 6.86-6.82 (m, 1H), 4.62-
4.56 (m, 1H), 4.5-4.44 (m, 1H), 4.1-3.98 (m, 3H), 3.43 (s, 3H); EI-MS 
(m/z): 302 (M+H+, 100%), 304 (63%). Anal.Cald.for C12H13Cl2N3O2: C, 
47.70; H, 4.34; Cl, 23.47; N, 13.91; O, 10.59; Found: C, 47.71; H, 4.33; 
Cl, 23.48; N, 13.89; O, 10.58 
1-[1-(2,4-dichlorophenoxy)-3-methoxypropan-2-yl]-1H-1,2,4-
triazole, 4a: Semisolid, FT-IR (KBr, cm-1): 3053, 2931, 1503, 1482, 
1288, 1132, 1105, 1012, 746; 1H NMR (CDCl3, 300MHz): δ 8.7 (s, 1H), 
8.15 (s, 1H), 7.35(s, 1H), 7.2-7.15 (m, 1H), 6.85-6.80 (m, 1H), 5.0-
4.95 (m, 1H), 4.45-4.38 (m, 2H), 3.98-3.92 (m, 2H), 3.4 (s, 3H); EI-MS 
(m/z): 302 (M+H+, 100%), 304 (63%); Anal.Cald.for C12H13Cl2N3O2: 
C, 47.70; H, 4.34; Cl, 23.47; N, 13.91; O, 10.59; Found: C, 47.71; H, 
4.35; Cl, 23.46; N, 13.90; O, 10.60 
1-[3-(3,4-dichlorophenoxy)-2-methoxypropyl]-1H-1,2,4-
triazole, 3b: Semisolid: FT-IR (KBr, cm-1): 3053, 2931, 1503, 1482, 
1288, 1132, 1105, 1012, 746; 1H NMR (CDCl3, 300MHz): δ 8.18 (s, 
1H), 7.98 (s, 1H), 7.38-7.36 (m, 1H), 7.05 (s, 1H), 6.8-6.78 (m, 1H), 
4.5-4.4 (m, 1H), 4.4-4.3 (m, 1H), 4.1-3.9 (m, 3H), 3.4 (s, 3H); EI-MS 
(m/z): 302 (M+H+, 100%), 304 (63%); Anal.Cald.for C12H13Cl2N3O2: 
C, 47.70; H, 4.34; Cl, 23.47; N, 13.91; O, 10.59; Found: C, 47.71; H, 
4.34; Cl, 23.46; N, 13.90; O, 10.58 
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1-[1-(3,4-dichlorophenoxy)-3-methoxypropan-2-yl]-1H-1,2,4-
triazole, 4b: Viscous gum: FT-IR (KBr, cm-1): 3053, 2931, 1503, 
1482, 1288, 1132, 1105, 1012, 746; 1H NMR (CDCl3, 300MHz): δ 8.25 
(s, 1H), 7.98 (s, 1H), 7.38-7.22 (m, 1H), 7.0 (s, 1H), 6.8-6.7 (m, 1H), 
4.9-4.8 (m, 1H), 4.4-4.3 (m, 2H), 3.9-3.8 (m, 2H), 3.4 (s, 3H); EI-MS 
(m/z): 302 (M+H+, 100%), 304 (63%); Anal.Cald.for C12H13Cl2N3O2: 
C, 47.70; H, 4.34; Cl, 23.47; N, 13.91; O, 10.59; Found: C, 47.70; H, 
4.35; Cl, 23.49; N, 13.92; O, 10.60 
1-[3-(2,6-dichlorophenoxy)-2-methoxypropyl]-1H-1,2,4-
triazole, 3c: Semisolid; FT-IR(KBr, cm-1): 3053, 2931, 1503, 1482, 
1288, 1132, 1105, 1012, 746; 1H NMR (CDCl3, 300MHz): δ 8.21 (s, 
1H), 7.98 (s, 1H), 7.38-7.1 (m, 2H), 7.10-7.05 (m, 1H), 4.70-4.61 (m, 
1H), 4.6-4.5 (m, 1H), 4.3-4.2 (m, 1H), 4.1-3.9 (m, 2H), 3.4 (s, 3H); EI-
MS (m/z): 302 (M+H+,100%), 304 (63%); Anal.Cald.for 
C12H13Cl2N3O2: C, 47.70; H, 4.34; Cl, 23.47; N, 13.91; O, 10.59; Found: 
C, 47.70; H, 4.33; Cl, 23.48; N, 13.92; O, 10.58. 
1-[1-(2,6-dichlorophenoxy)-3-methoxypropan-2-yl]-1H-1,2,4-
triazole, 4c: Gum; FT-IR(KBr, cm-1): 3053, 2931, 1503, 1482, 1288, 
1132, 1105, 1013, 751; 1H NMR (CDCl3, 300MHz): δ 8.5 (s, 1H), 7.98 
(s, 1H), 7.38-7.22 (m, 2H), 7.1-7.0 (m, 1H), 4.9-4.8 (m, 1H), 4.4-4.3 
(m, 2H), 3.9-3.8 (m, 2H), 3.4 (s, 3H); EI-MS (m/z): 302 (M+H+,100%), 
304 (63%); Anal.Cald.for C12H13Cl2N3O2: C, 47.70; H, 4.34; Cl, 23.47; 
N, 13.91; O, 10.59; Found: C, 47.72; H, 4.36; Cl, 23.49; N, 13.93; O, 
10.62. 
1-[3-(3-chlorophenoxy)-2-methoxypropyl]-1H-1,2,4-triazole, 
3d: Semisolid; FT-IR (KBr, cm-1): 3051, 2930, 1504, 1488, 1282, 
1133, 1106, 1012, 741; 1H NMR (CDCl3, 300MHz): δ 8.19 (s, 1H), 7.98 
(s, 1H), 7.3-7.2 (m, 1H), 7.0-6.98 (m, 1H), 6.9 (s, 1H), 6.81-6.79 (m, 
1H), 4.5-4.3 (m, 2H), 4.1-3.9 (m, 3H), 3.4 (s, 3H); EI-MS (m/z): 268 
(M+H+, 100%), 270 (32%); Anal.Cald.for: C12H14ClN3O2: C, 53.84; H, 
5.27; Cl, 13.24; N, 15.70; O, 11.95; Found; C, 53.85; H, 5.28; Cl, 13.25; 
N, 15.72; O, 11.96 
1-[1-(3-chlorophenoxy)-3-methoxypropan-2-yl]-1H-1,2,4-
triazole, 4d: Gum; FT-IR (KBr, cm-1): 3051, 2930, 1504, 1488, 1282, 
1133, 1106, 1012, 741; 1H NMR (CDCl3, 300MHz): δ 8.5 (s, 1H), 7.98 
(s, 1H), 7.3-7.2 (m, 1H), 7.0-6.98 (m, 1H), 6.9 (s, 1H), 6.81-6.79 (m, 
1H), 4.9-4.8 (m, 1H), 4.4-4.3 (m, 2H), 3.92-3.8 (m, 2H), 3.39 (s, 3H); 
EI-MS (m/z): 268 (M+H+, 100%), 270 (32%); Anal.Cald.for: 
C12H14ClN3O2: C, 53.84; H, 5.27; Cl, 13.24; N, 15.70; O, 11.95; Found; 
C, 53.86; H, 5.29; Cl, 13.23; N, 15.73; O, 11.97 
1-[3-(4-chlorophenoxy)-2-methoxypropyl]-1H-1,2,4-triazole, 
3e: Semisolid; FT-IR (KBr, cm-1): 3051, 2930, 1504, 1488, 1282, 
1133, 1106, 1012, 741; 1H NMR (CDCl3, 300MHz): δ 8.19 (s, 1H), 7.99 
(s, 1H), 7.3-7.2 (m, 2H), 6.9-6.8 (m, 2H), 4.5-4.3(m, 2H), 4.1-3.9 (m, 
3H), 3.39 (s, 3H); EI-MS (m/z): 268 (M+H+, 100%), 270 (32%); 
Anal.Cald.for: C12H14ClN3O2: C, 53.84; H, 5.27; Cl, 13.24; N, 15.70; O, 
11.95; Found; C, 53.85; H, 5.28; Cl, 13.25; N, 15.72; O, 11.96 
1-[1-(4-chlorophenoxy)-3-methoxypropan-2-yl]-1H-1,2,4-
triazole, 4e: Gum; FT-IR (KBr, cm-1): 3051, 2930, 1504, 1488, 1282, 
1133, 1106, 1012, 741; 1H NMR (CDCl3, 400MHz): δ 8.3 (s, 1H), 8.0 
(s, 1H), 7.3-7.2 (m, 2H), 6.9-6.8 (m, 2H), 4.9-4.8 (m, 1H), 4.4-4.3 (m, 2H), 
3.9-3.8 (m, 2H), 3.39 (s, 3H); EI-MS (m/z): 268 (M+H+, 100%), 270 
(32%); Anal.Cald.for: C12H14ClN3O2: C, 53.84; H, 5.27; Cl, 13.24; N, 15.70; 
O, 11.95; Found; C, 53.87; H, 5.28; Cl, 13.23; N, 15.71; O, 11.96 
1-[3-(3,5-dimethylphenoxy)-2-methoxypropyl]-1H-1,2,4-
triazole, 3f: Semisolid; FT-IR (KBr, cm-1): 3056, 2929, 1506, 1486, 
1278, 1136, 1107, 1013, 745; 1H NMR (DMSO, 300MHz): δ 8.5 (s, 
1H), 7.98 (s, 1H), 6.58 (s, 3H), 4.5-4.35 (m, 2H), 4.1-4.0 (m, 1H), 4.0-
3.8 (m, 2H), 3.3 (s, 3H), 2.22 (s, 6H); EI-MS (m/z): 262 (M+H+, 
100%); Anal.Cald.for: C14H19N3O2; C, 64.35; H, 7.33; N, 16.08; O, 
12.25; Found; C, 64.36; H, 7.35; N, 16.07; O, 12.26 
1-[1-(3,5-dimethylphenoxy)-3-methoxypropan-2-yl]-1H-1,2,4-
triazole, 4f: Semisolid; FT-IR (KBr, cm-1): 3055, 2930, 1504, 1488, 
1282, 1133, 1106, 1012, 745; 1H NMR (DMSO, 300MHz): δ 8.3 (s, 
1H), 8.0 (s, 1H), 6.78 (s, 3H), 4.9-4.8 (m, 1H), 4.4-4.3 (m, 2H), 3.9-3.8 
(m, 2H), 3.3 (s, 3H), 2.22 (s, 6H); EI-MS (m/z): 262 (M+H+, 100%); 
Anal.Cald.for: C14H19N3O2; C, 64.35; H, 7.33; N, 16.08; O, 12.25; 
Found; C, 64.37; H, 7.35; N, 16.08; O, 12.28 
RESULTS AND DISCUSSION 
Antibacterial activity  
The antibacterial activity of all the synthesized compounds were 
examined against different Gram-positive (Bacillus subtilis and 
Staphylococcus aureus) and Gram-negative (Escherichia coli and 
Salmonella typhi) organisms by measuring zone of inhibition. The 
antibacterial activity was performed by Agar diffusion method at the 
concentration level of 100μg/ml. Ciprofloxacin (A) was used as 
standard drug at a concentration of 100 μg/ml. Nutrient agar was 
used as culture media and DMSO was used as solvent control. The 
results of the antibacterial activity are shown in Table 2. 
Antifungal activity  
The antifungal activity of all the synthesized compounds were 
examined against Aspergillus niger and Candida albicans by 
measuring zone of inhibition. The antifungal activity was performed 
by Agar diffusion method at the concentration level of 100μg/ml. 
Ketoconazole (B) was used as standard drug at a concentration of 
100μg/ml. Sabouraud dextrose agar was used as culture media and 
DMSO was used as solvent control. The results of the antifungal 
activity are shown in Table 2. 
 
Table 2: Zone of inhibition (mm) data of synthesized compounds 
S. No. Compound B. subtilis  S. aureus  E. coli  S. typhi  A. niger  C. albicans 
1 3a 13  12 14 12 15 13 
2 3b 14 13 14 11 14 12 
3 3c 14 13 15 12 15 13 
4 3d 11 10 12 11 10 09 
5 3e 12 11 10 11 10 08 
6 3f 09 08 08 07 09 07 
7 4a 14 13 15 12 15 14 
8 4b 13 12 14 13 14 13 
9 4c 14 13 15 14 15 13 
10 4d 11 10 10 11 12 11 
11 4e 10 11 11 12 12 11 
12 4f 08 07 07 06 08 09 
13 A 16 15 17 16 - - 
14 B - - - - 18 16 
A=Ciprofloxacin and B=Ketoconazole.  
 
CONCLUSION 
It would be seen from Table 2 that the compound 3(a-c) and 4(a-c) 
exhibit significant antibacterial activity against both Gram negative 
and Gram Positive organisms and the rest of the compounds show 
poor antibacterial activity against Gram negative and Gram Positive 
organisms. Table 2 also indicates that the significant antifungal 
activity is exhibited by the compounds 3(a-c) and 4(a-c) and the 
Reddy et al. 
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rest of the compounds showed no significant antifungal activity 
against both fungi. It clearly indicates that the compounds 3(a-c) 
and 4(a-c) with dichloro substitution exhibited highest microbial 
activity among all the rest of the compounds. 
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